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Liver damage observed in cystic fibrosis is a complicated process comprised of 
fibrogenesis, inflammation, remodeling, apoptosis, and cholestasis. Complexity 
of processes which take place in the liver and bile ducts in the course of this disease 
are not clearly defined. Changes in the liver are observed in 5–20% of patients with 
diagnosed cystic fibrosis; however they can increase mortality, shorten time of life, 
and deteriorate quality of life. The aim of the chapter was to review the risk factors, 
clinical symptoms, diagnostic methods, and treatment of liver changes in the course 
of cystic fibrosis.
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1. Introduction
Hepatic lesions concern only 5–20% of patients with diagnosed cystic fibrosis. 
However they increase the level of fatalities, shorten the survival rate, and impair 
the quality of life. Liver diseases are the most common, non-pulmonary cause 
of death among patients with cystic fibrosis. They most often occur in the first 
decade of life. Cirrhosis is detected in about 10% of CF children under the age of 18 
compared to 2% of adults with the same condition. The average age of the CF liver 
disease manifestation is about 10 years [1–7].
1.1 Etiopathogenesis of liver’s change in patients with cystic fibrosis
Liver and bile duct diseases are a combination of complex processes of fibrosis, 
inflammation, remodeling, apoptosis, and cholestasis. They are a consequence 
of the abnormal functioning of the CFTR protein, immunologic reactions, and 
response to oxidative stress [5, 8–11].
1.1.1 Pathophysiological changes to the bile acids in the course of cystic fibrosis
The important roles played by the pathophysiological changes of the bile duct 
include changes to the components of the bile (abnormal water and electrolyte 
contents and change to the pH of the bile) and changes to the profile of bile 
acids—to hydrophobic, abnormal transport of the bile, retention of toxic bile acids 
(taurocholic acid), and induction of pro-inflammatory chemokines which influ-
ence on biliary fibrogenesis. Factors contributing to the processes of precipitation 
of bile acids in the bile ducts include decreased synthesis of the salts of the bile 
acids, decreased absorption of bile acids from the lumen of the small intestine, and 
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narrowing of the bile ducts impairing the outflow of the bile from the liver to the 
lumen of the duodenum [5, 8, 10].
1.1.2 Genetic factors
So far, no specific mutation relating solely to liver damage in the course of 
cystic fibrosis has been discovered. Most commonly, these are the so-called “seri-
ous mutations” of the CFTR gene (delta F508,G524X, N1303K, CFTRdel21kB, 
1811 + 1G- > C). The delta F508 mutation plays a particular role in the develop-
ment of hepatic lesions in the course of cystic fibrosis due to its stimulation of 
an increased loss of bile acids with stools and the fact that it leads to the forma-
tion of more hydrophobic bile acids. Hepatic lesions co- occurring with cystic 
fibrosis in patients with the 3849 + 10kB C- > T mutation have not yet been the 
subject of interest. However, the clinical course in patients with diagnosed cystic 
fibrosis and the same mutation of the CFTR gene tends to vary. There is no strict 
phenotype–genotype corelation. The role of the SERPINE1 mutation: it occurs in 
about 2% of the patients with cystic fibrosis and in about 5% of the patients with 
cystic fibrosis and co-occurring hepatic lesions. Responsible for the synthesis 
of the inhibitor of serine protease. The protein connected to allele Z is concen-
trated within the endoplasmic reticulum of hepatocytes leading to their damage, 
inflammation, and cirrhosis. In about 10% of allele Z homozygotes, the accu-
mulation of the SERPINA gene protein leads to neonatal hepatitis and in 2–3% 
of cases to fibrosis and cirrhosis. In pathogenesis some genes were suspected as a 
factor inducing pathological processes in the liver and bile duct in patients with 
cystic fibrosis (gene of plasminogen activator inhibitor type 1, genes relating to 
metalloproteinases, P1 glutation s-transferase gene, transforming growth factor 
beta gene, uridylyltransferase gene (UGT1A1). But the role is not strictly con-
firmed [12–17].
1.1.3 Immunological factors
Chemokines play a role as an activator of stellate cells (source: hepatic macro-
phages, endothelial cells, bile duct epithelial cells, lymphocytes, blood platelets, 
and hepatocytes). The main chemokines are monocyte chemoattractant pro-
tein-1 (MCP1), macrophage inflammatory protein-1 beta (MIP1B), TGF-beta, 
TNF-alpha, platelet-derived growth factor (PDGF), and interleukins IL-1, IL-6, 
and IL-10 [11, 18–23].
Pathogenesis of hepatic lesions the course of cystic fibrosis according to 
Colombo [1, 2, 8].
   Abnormalities of cholangiocytes.
     ↓
         Mucous plugs in bile ducts.
     ↓
            Inflammatory and proliferative processes.
     ↓
         Focal biliary fibrosis (25–30%).
     ↓
                   Multilobular biliary cirrhosis (10%).
     ↓
                 Portal hypertension.
     ↓
                 Hepatic insufficiency.
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1.2 Organ lesions contributing to the manifestation of CFLD
In the examination of Wilchanski et al., the presence of hepatic lesions (cystic 
fibrosis liver damage (CFLD)) was concluded in 28% (80/288) of CF patients. 
All patients with hepatic lesions were diagnosed with pancreatic insufficiency. 
No correlation between the occurrence of hepatic lesions and pulmonary lesions, 
respiratory insufficiency, the level of malnutrition, meconium ileus, and/or distal 
intestinal obstruction syndrome (DIOS) was concluded [24]. Lindblad observed 
meconium ileus in only 12% of CF patients, out of whom only 6/15 patients with 
meconium ileus had the symptoms of liver damage [6]. Siano did not prove the 
correlation between the occurrence of hepatic lesions in the course of cystic fibrosis 
and the pancreatic efficiency and the level of nutrition. In 2–5% of patients, focal 
biliary cirrhosis develops into multilobular cirrhosis [25].
1.2.1 Nutritional factors
Malnutrition influences on liver function in children with cystic fibrosis. Children 
with diagnosed cystic fibrosis and liver damage have lower body mass, height, 
circumference of the upper arm, and BMI. Patients with cystic fibrosis also have 
significantly lower levels of linoleic (LA), docosahexaenoic (DHA), and docosa-
pentaenoic (DPA) acids. The influence of parenteral nutrition and antioxidant and 
vitamin deficiency is confirmed [26–29]. Sometimes in children with cystic fibrosis 
especially with meconium ileus, total parenteral nutrition is necessary. Total paren-
teral nutrition (TPN) therapy is a well-recognized cause of liver injury. The histologic 
changes attributed to TPN in the literature vary widely. Total parenteral nutrition-
induced liver disease develops in 40–60% of infants who require long-term TPN. The 
clinical spectrum includes cholestasis, cholelithiasis, hepatic fibrosis with progression 
to biliary cirrhosis, and the development of portal hypertension and liver failure in 
a significant number of children who are totally parenterally fed. The pathogenesis 
is multifactorial and is related to prematurity, low birth weight, and duration of 
TPN. The degree and severity of the liver disease are related to the recurrent sepsis 
including catheter sepsis, bacterial translocation, and cholangitis. The lack of enteral 
feeding leading to reduced gut hormone secretion, reduction of bile flow, and biliary 
stasis may be important mechanisms in the development of cholestasis, biliary sludge, 
and cholelithiasis.
1.2.2 The role of medications
In patients with cystic fibrosis, abnormal functions of oxidases and P450, 
CYP2C8, CYP2C9, and CYP3A4 cytochromes are observed. The dose of beta-lactam 
should be reduced by 20%. The doses of aminoglycosides should be decided upon 
depending on the level of the medication in the blood serum. Increased microsomal 
metabolism relating to theophylline and methylxanthine through the affected first 
phase of the biotransformation of the medications. Increased hepatic clearance of 
the second phase, which may be reflected in the abnormal metabolism of furose-
mide, lorazepam, and ibuprofen [30–32].
1.2.3 Defects of the gall bladder and bile ducts
In about 30% of patients with cystic fibrosis, atrophic gall bladder, or the lack 
thereof, also its defects and/or of bile ducts is reported. No correlation between 
cirrhosis and abnormalities in the gall bladder and/or bile ducts has been observed. 
Gallbladder hydrops and lithiasis are more commonly observed in patients with 
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cystic fibrosis than the healthy population. The narrowing of the distal regions of 
the bile ducts is frequent and may occur in even 90% of CF patients and contribute 
to the formation of gallstones [33, 34].
1.2.4 Cholelithiasis
Cholelithiasis concerns 14–24% of CF patients. The following play a role in the 
pathogenesis of the formation of gallstones: abnormal bile content, increased excre-
tion of bile acids with stools, and the formation of lithogenic bile where bile acids 
are interlocked with glycine. No correlation between the formation of gallstones 
and supplementation with pancreatic enzymes has been confirmed [1, 3, 22].
Risk factors for the development of liver diseases in cystic fibrosis:
1. Male gender—three fourths of patients with CFLD are male. Protective role of 
estrogens in female.
2. Coexisting meconium ileus (inconsistent data—from a five-time higher risk of 
developing hepatic lesions to a similar risk). Only 25% of patients with CFLD 
who had meconium ileus in the medical interview was identified. Meconium 




5. Severe genotype (delta F508) [1, 12, 24, 35, 36].
1.3 Clinical picture
In most CF patients, the course of hepatic complications is symptomless. 
Pruritus sometimes occurs and jaundice in patients whose condition is advanced. 
Incidental finding of hepatomegaly is usually the first sign. In newborns, steatosis 
may be incidentally discovered in a routine abdominal ultrasound.
Clinical changes of the liver in patients with cystic fibrosis:
1. Focal hepatic fibrosis (72%)
2. Focal biliary cirrhosis (20–30%)
3. Multilobular biliary cirrhosis (5–15%)
4. Portal hypertension (2–5%)
5. Small atrophic gallbladder and narrowing of bile ducts (15–45%)
6. Cholelithiasis (14–24%)
7. Steatosis (25–60%)
8. Cholestasis in newborns (<10%)
9. Primary sclerosing cholangitis (rarely)
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10. Cholangiocarcinoma (rarely)
11. Drug-induced, toxic liver damage [1, 3, 12, 24, 37, 39–41]
1.3.1 Laboratory tests
1.3.1.1 Periodic laboratory tests
The levels of AlAT, AspAT, GGTP, bilirubin and bile acids, the APRI index, and 
FibroTest are recommended. It is believed that elevated levels of at least two hepatic 
parameters above the norm within at least 3 months is an indication of advancing 
hepatic lesions. But they have low sensitivity and specificity. Most patients with 
multifocal cirrhosis have normal test results. Isolated elevation of aminotransfer-
ases with concurrent normal GGTP index may indicate steatosis.
1.3.1.2 Abdominal ultrasound with a Doppler option and elastography
Ultrasound is inexpensive and is a noninvasive test. It allows assessment of the level 
of steatosis, symptoms of portal hypertension, and cirrhotic transformation of the liver. 
However, normal imaging of the liver does not exclude the ongoing process of fibrosis.
FibroScan is an effective and noninvasive tool to quantify fibrosis and steatosis 
in the liver diseases including cystic fibrosis. The stiffness of the liver tissue can be 
assessed based on shear wave velocity (the stiffness increases with the speed).
1.3.1.3 Liver biopsy with histopathological assessment.
Liver biopsy is an invasive procedure and is prone to side effects and sampling. 
This is not a routine recommended procedure in patients with CFLD.
1.3.1.4 Noninvasive parameters of liver fibrosis
Fibroindex, aminopeptides of type III procollagen, collagen I, collagen IV, 
laminine, hyaluronic acid, and/or cytokines and chemokines relating to the process 
of fibrosis. There are studies on their usefulness in minimally invasive clinical 
diagnostics [27, 42–49].
1.4 Treatment
1. Background therapy of cystic fibrosis include pancreas enzyme supplemen-
tation, vitamin supplementation, extensive physiotherapy, and nutritional 
support,
2. Diet therapy. In patients with cystic fibrosis, nutrition and survival are inti-
mately related. Growth failure and body mass deficiency are the prognostic 
factors in patients with CF. Prevention of undernourishment in cystic fibrosis, 
sometimes feeding tube or PEG nutrition, is recommended. Hypercaloric 
diet, which is rich in protein, carbohydrates, and fat, is recommended. 
The energy needs of patients with CF vary widely and have been stated as 
120–150% of those required by healthy individuals of the same age, sex, and 
size. Reduction of protein only in situation of encephalopathy. Correction 
of fat-soluble vitamin deficiency is essential. Lower serum levels of vitamin 
A and E were associated with a higher rate of pulmonary exacerbations and 
worse liver function.
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3. Ursodeoxycholic acid (UDCA). UDCA has a cytoprotective effect on the 
cell membranes of cholangiocytes. It stimulates the secretion of chloride ions 
through calcium-dependent chloride channel. It reduces the ratio of cholic acid 
in bile (less than 5%), reduces its synthesis, and lowers its overall volume. It 
also stimulates cholangiocytes and hepatocytes to secrete. It has antiapoptotic 
effect and reduces the toxic effects of hydrophobic bile acids.
The dose is 15–20 mg/kg b.m. in two divided doses over 24 hours.
There are only a few clinical trials assessing the effectiveness of ursodeoxycholic 
acid. There is insufficient evidence to justify its routine use in cystic fibrosis as a 
preventative measure. Present data suggesting that UDCA should be started before 
severe liver damage is present as it might be able to prevent the progression of CFLD 
and has the potential to induce a reversal of fibrosis [1, 2, 4, 38, 41, 50, 51].
4. The treatment of portal hypertension should include:
• Beta blockers—mild oesophageal varices in patiens without contrindications
• Endoscopic methods for the treatment of severe oesophageal varices [37, 51–53]
5. Liver transplant. Advancing dysfunction of the liver, progressing ascites 
and jaundice, recurrent bleeding from esophageal varices and hepatopulmonary 
syndrome, and recurring peritonitis and hepatocarcinoma are indications for liver 
transplantation. MELD/PELD scores are helpful to evaluate the eligibility for liver 
transplantation. Model for End-Stage Liver Disease (MELD) includes bilirubin 
level, albumin, and creatinine concentration. Pediatric end-stage liver disease 
(PELD) consists of age, bilirubin level, INR index, albumin concentration. PELD/
MELD score obtained upon admission may be of help to establish the optimal 
timing for LT evaluation and listing. A higher score correlates with a more critical 
condition and worse survival.
In patients with cystic fibrosis following isolated liver transplantation, there is 
an increased risk of pulmonary complications (severe infections). It seems that an 
FEV1 < 50% was associated with poor outcomes in isolated liver transplantation, 
and thus patients with poor lung function should be considered for combined 
lung-liver transplantation. For isolated liver transplantation, if the FEV1 is <40%, 
patients are listed with their MELD/PELD score plus a 10% mortality equivalence. 
If listed for a combined liver-lung transplantation with an FEV1 < 40%, the liver 
listing starts with a MELD of 40 [54, 55]. Simultaneous liver-pancreas transplanta-
tion restores exocrine and endocrine pancreatic function in patients with CFLD and 
enables improved nutritional outcomes concurrent with the potential for discon-
tinuation of insulin and pancreatic enzyme supplementation therapies. Diabetes 
has been reported to exert a negative effect on the already decreased pulmonary 
function, observed in CF patients. FEV1 in CF patients with diabetes is markedly 
reduced in all age groups compared to CF patients without diabetes. Simultaneous 
liver-pancreas transplantation is associated with an improved BMI in the post-
transplant course [57, 58].
The outcome for combined heart/lung/liver grafting in adult people with CF 
was poor, whereas liver transplantation alone had acceptable waiting times and 
good survival outcome. High incidence of renal impairment in this group, and in 
contrast to previous studies, largely in pediatric patients, respiratory function can 
decline dramatically [55, 56, 59–61].
European recommendations for the treatment of cystic fibrosis and hepatic lesions:
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1. Biochemical tests (AlAT, AspAT, GGTP, FA, prothrombin time, blood plate-
lets) every 6 months.
2. Imaging tests—abdominal ultrasound with Doppler option and elastography, 
alternatively annual CT or MR.
3. Ursodeoxycholic acid at 20 mg/ g daily with divided doses being more 
effective.
4. Panendoscopy performed every 2–3 years is necessary in patients with cirrho-
sis and or splenomegaly in order to exclude esophageal varices.
5. Assessment of the hepatopulmonary syndrome—assessment of intrapulmo-
nary shunts as they intensify hypoxemia.
6. In the case of cirrhosis—assessment of the levels of alpha-fetoprotein (AFP) 
every 6 months.
7. Mild esophageal varices—nonselective beta blockers? Level 2–3 varices—
endoscopic treatment or intrahepatic portosystemic shunts.
8. Prevention of undernutrition (via feeding tube or PEG).
2. Summary
1. The etiopathogenesis of hepatic lesions in the course of cystic fibrosis is very 
complex and not yet fully explained.
2. The clinical symptoms of CFLD are not characteristic, and the clinical picture 
is often symptomless or limited.
3. Further studies into the causes of hepatic lesions in cystic fibrosis are neces-
sary, which will contribute to the reduction in the number of deaths, extended 
survival rate, and improvement in patients’ quality of life.
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